LENZ THERAPEUTICS INC (LENZ) competitors & alternatives
Health Care · NASDAQ
LENZ THERAPEUTICS INC (LENZ)'s top competitors and alternatives — its most similar public companies — include AbbVie (ABBV), AMNEAL PHARMACEUTICALS INC CLASS A (AMRX), STAAR SURGICAL (STAA), Aldeyra Therapeutics, Inc. (ALDX), TARSUS PHARMACEUTICALS INC (TARS), SPYGLASS PHARMA INC SHS (SGP), KINIKSA PHARMACEUTICALS INTERNATIO (KNSA), Outlook Therapeutics, Inc. (OTLK), LINEAGE CELL THERAPEUTICS INC (LCTX), GLAUKOS CORP (GKOS), EYEPOINT INC (EYPT) and ABEONA THERAPEUTICS INC (ABEO). These are LENZ THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top LENZ competitors & alternatives
-
AbbVieABBVHealth Care
Global biopharmaceutical company with leadership positions in immunology, neuroscience, oncology, and aesthetics targeting complex diseases.
$253.30 (as of 2026-07-22) · market cap $452.5B
-
AMNEAL PHARMACEUTICALS INC CLASS AAMRXHealth Care
Amneal Pharmaceuticals is a diversified biopharma company providing a broad range of essential, affordable generic and specialty medicines, alongside…
$17.75 (as of 2026-07-22) · market cap $5.7B
-
STAAR SURGICALSTAAHealth Care
STAAR Surgical designs and manufactures implantable collamer lenses (ICLs) for refractive vision correction, offering reversible alternatives to corneal…
$24.71 (as of 2026-07-22) · market cap $1.2B
-
Aldeyra Therapeutics, Inc.ALDXHealth Care
Aldeyra is a clinical-stage biotech pursuing FDA approval of reproxalap, an aldehyde dehydrogenase activator for ophthalmologic inflammation, dependent on…
$1.70 (as of 2026-07-22) · market cap $106M
-
TARSUS PHARMACEUTICALS INCTARSHealth Care
Tarsus Pharmaceuticals commercializes XDEMVY, the first FDA-approved treatment for Demodex blepharitis, with a pipeline of lotilaner-based therapies for ocular…
$57.58 (as of 2026-07-22) · market cap $2.5B
-
SPYGLASS PHARMA INC SHSSGPHealth Care
Spyglass Pharma is a clinical-stage biotech developing an innovative sustained-release drug delivery platform to improve patient outcomes in cataract surgery.
$20.54 (as of 2026-07-22) · market cap $682M
-
KINIKSA PHARMACEUTICALS INTERNATIOKNSAHealth Care
Kiniksa is a biopharmaceutical company commercializing ARCALYST (IL-1 cytokine trap) for recurrent pericarditis and rare inflammatory diseases, with a pipeline…
$62.44 (as of 2026-07-22) · market cap $4.8B
-
Outlook Therapeutics, Inc.OTLKHealth Care
Outlook Therapeutics develops ophthalmic biologics for retinal diseases, with its lead product LYTENAVA (bevacizumab gamma) approved in Europe and under FDA…
$1.34 (as of 2026-07-22) · market cap $212M
-
LINEAGE CELL THERAPEUTICS INCLCTXHealth Care
Lineage Cell Therapeutics develops allogeneic cell therapy treatments for serious human diseases through its AlloSCOPE™ manufacturing platform and partnerships…
$1.11 (as of 2026-07-22) · market cap $278M
-
GLAUKOS CORPGKOSHealth Care
Glaukos is a specialized ophthalmic company transforming eye care through innovative Micro-Invasive Glaucoma Surgery devices and proprietary sustained-release…
$152.86 (as of 2026-07-22) · market cap $8.9B
-
EYEPOINT INCEYPTHealth Care
EyePoint Pharmaceuticals is a clinical-stage biopharma developing sustained-release treatments for retinal diseases including wet AMD and diabetic macular…
$12.66 (as of 2026-07-22) · market cap $1.1B
-
ABEONA THERAPEUTICS INCABEOHealth Care
Abeona is a commercial-stage biopharmaceutical company that just received FDA approval for ZEVASKYN®, the first and only autologous cell-based gene therapy for…
$6.42 (as of 2026-07-22) · market cap $374M
Not quite? Describe exactly what you want →
Peers are LENZ THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: LENZ THERAPEUTICS INC (LENZ).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.